Cargando…
Efficacy and Safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study
BACKGROUND: Ocedurenone (KBP-5074), a nonsteroidal mineralocorticoid receptor antagonist, is documented to lower blood pressure in patients with stage 3b/4 chronic kidney disease (CKD) with uncontrolled or resistant hypertension (BLOCK-CKD study). However, the efficacy and safety of Ocedurenone in s...
Autores principales: | Bakris, George L, Yang, Y Fred, McCabe, James M, Liu, Jin Rong, Tan, Xiaojuan J, Benn, Vincent J, Pitt, Bertram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570658/ https://www.ncbi.nlm.nih.gov/pubmed/37471468 http://dx.doi.org/10.1093/ajh/hpad066 |
Ejemplares similares
-
Pharmacokinetics and Drug–Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo
por: Wang, Ping, et al.
Publicado: (2023) -
CKD hotspots around the world: announcement
Publicado: (2014) -
QT interval in CKD and haemodialysis patients
por: Di Iorio, Biagio, et al.
Publicado: (2013) -
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
por: Rossing, Peter, et al.
Publicado: (2021) -
Cost analysis for cancer subgroups
por: Hall, P S, et al.
Publicado: (2009)